[go: up one dir, main page]

DK133035B - Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt - Google Patents

Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt

Info

Publication number
DK133035B
DK133035B DK378571AA DK378571A DK133035B DK 133035 B DK133035 B DK 133035B DK 378571A A DK378571A A DK 378571AA DK 378571 A DK378571 A DK 378571A DK 133035 B DK133035 B DK 133035B
Authority
DK
Denmark
Prior art keywords
analgetic
euphorical
parentally
procedure
remove
Prior art date
Application number
DK378571AA
Other languages
Danish (da)
English (en)
Inventor
I J Pachter
M Gordon
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DK133035B publication Critical patent/DK133035B/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK378571AA 1970-08-03 1971-08-03 Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt DK133035B (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6062170A 1970-08-03 1970-08-03

Publications (1)

Publication Number Publication Date
DK133035B true DK133035B (da) 1976-03-15

Family

ID=22030682

Family Applications (1)

Application Number Title Priority Date Filing Date
DK378571AA DK133035B (da) 1970-08-03 1971-08-03 Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt

Country Status (9)

Country Link
US (1) US3773955A (fr)
AU (1) AU463074B2 (fr)
BE (1) BE770625A (fr)
DE (1) DE2138593A1 (fr)
DK (1) DK133035B (fr)
FR (1) FR2101191B1 (fr)
GB (1) GB1353815A (fr)
NL (1) NL7109388A (fr)
ZA (1) ZA714683B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3896226A (en) * 1971-11-26 1975-07-22 Lewinstein Evalina 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3906100A (en) * 1973-05-24 1975-09-16 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56128715A (en) * 1980-03-06 1981-10-08 Bristol Myers Co Analgesic abuse prevention
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3216327C1 (de) * 1982-05-03 1983-05-19 Siempelkamp Gießerei GmbH & Co, 4150 Krefeld Herstellung von dickwandigen Abschirmtransport- und Lagerbehältern aus sphärolitischem Gußeisen
AU8952282A (en) * 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
HU219332B (hu) 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
US7027859B1 (en) 1994-09-26 2006-04-11 Alza Corporation Electrotransport delivery device having improved safety and reduced abuse potential
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
EP1685839B8 (fr) 1997-12-22 2013-06-26 Euro-Celtique S.A. Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste et un antagoniste des récepteurs opiacés
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
CA2380524A1 (fr) 1999-08-25 2001-03-01 Barrett R. Cooper Compositions et procedes permettant de traiter l'intolerance aux opiaces
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DK2517710T3 (en) 2000-02-08 2015-05-26 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2003002100A1 (fr) * 2001-06-26 2003-01-09 Farrell John J Systeme d'administration de narcotique inviolable
DE60230632D1 (de) 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
EP2425824B1 (fr) 2002-04-05 2017-05-10 Euro-Celtique S.A. Préparation pharmaceutique contenant de l'oxycodone et de la naloxone
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
ATE501712T1 (de) * 2002-04-23 2011-04-15 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2491572C (fr) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2422775A3 (fr) 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US9579286B2 (en) 2003-04-21 2017-02-28 Purdue Pharma L.P. Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004098567A2 (fr) 2003-04-30 2004-11-18 Purdue Pharma L.P. Forme posologique transdermique a fermeture inviolable
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP2269606A3 (fr) 2003-10-30 2012-04-25 ALZA Corporation Systèmes analgésiques transdermiques disposant d'un potentiel d'abus réduit
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP1691892B1 (fr) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Forme posologique co-extrudee inviolable contenant un principe actif et un principe contraire, et procede de fabrication
WO2005061033A1 (fr) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Traitement de douleur aigue par inhalation en aerosol de medicaments
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
MXPA06011122A (es) 2004-03-30 2007-03-21 Euro Celtique Sa Forma de dosis resistente a la manipulacion comprendiendo un adsorbente y un agente adverso.
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP2319499A1 (fr) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Medicament resistant contre l' alcohol
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP1895995A2 (fr) * 2005-05-13 2008-03-12 Alza Corporation Systeme d'administration de galantamine a couches multiples equipe d'une protection contre l ecoulement un flux de matiere de reservoir
US20090143761A1 (en) * 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
WO2006133102A2 (fr) * 2005-06-03 2006-12-14 Trans-Dermal Patents Company, Llc Systeme d'administration d'agent et ses utilisations
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
WO2007087452A2 (fr) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810670A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Combinaison de Polamidone et de Naloxone dans le traitement de la toxicomanie
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
US7748244B2 (en) * 2007-09-14 2010-07-06 Schlage Lock Company Deadbolt lock assembly
WO2009059050A2 (fr) * 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Modulateurs de tlr et leurs procédés d'utilisation
WO2009059048A2 (fr) * 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Opioïdes-(+) et méthodes d'utilisation
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2012219322A1 (en) 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2016101552A4 (en) 2015-09-03 2016-10-13 Acino Pharma Ag Reduction of the deallylation of naloxone during the storage of a naloxone-containing retard formulation
WO2017222575A1 (fr) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Procédé de préparation de formulations orales dissuasives d'abus plus stables
US10532385B2 (en) 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments
CA3090277A1 (fr) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Dispositif aerosol a condensation electrique

Also Published As

Publication number Publication date
BE770625A (fr) 1972-01-28
AU463074B2 (en) 1975-07-17
US3773955A (en) 1973-11-20
AU3185671A (en) 1973-02-01
GB1353815A (en) 1974-05-22
NL7109388A (fr) 1972-02-07
DE2138593A1 (de) 1972-03-30
FR2101191A1 (fr) 1972-03-31
FR2101191B1 (fr) 1975-02-07
ZA714683B (en) 1972-04-26

Similar Documents

Publication Publication Date Title
DK133035B (da) Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt
DK143799C (da) Fremgangsmaade til fremstilling af n-1,1,1-trisubstituerede methylazoler
DK137451B (da) Analogifremgangsmåde til fremstilling af derivater af 2-oxo-pyrrolidin.
SE389526B (sv) Knut for forbindning av flera balkar, serskilt vid byggnadsskelett
DK124748B (da) Analogifremgangsmåde til fremstilling af N-(fenylalkyl)-acylamider eller syreadditionssalte deraf.
DK127695B (da) Tårnstillads.
DK133682B (da) Analogifremgangsmåde til fremstilling af 3alfa-hydroxy-5alfa-pregn-1-en-20-oner eller 3alfa-hydroxy-17beta-alkoxykarbonyl-5alfa-androst-1-ener.
DK127431B (da) Analogifremgangsmåde til fremstilling af thiepinderivater eller syreadditionssalte deraf.
DK133869C (da) Fremgangsmade til fremstilling af alkalimetalaluminiumalkoxider
DK132121C (da) Fremgangsmade til fremstilling af 17alfa-hydroxypregna-4,9(11)-dien-3,20-dion
DK129239B (da) Analogifremgangsmåde til fremstilling af dihydro-3-(4-hydroxy-4-piperidyl)-furanonderivater.
TR17430A (tr) Sarsinti azaltici,polioreueretan terkipleri
DK126784B (da) Fremgangsmåde til fremstilling af hydroquinolinforbindelser eller hydroisoquinolinforbindelser.
DK130966B (da) Analogifremgangsmåde til fremstilling af 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-4-carboxylsyre-derivater eller syreadditionssalte deraf.
DK146015C (da) Analogifremgangsmaade til fremstilling af erythro- eller mesoformerne af 3,3'-difluor-4,4'-dihydroxydibenzylderivater
DK129124B (da) Analogifremgangsmåde til fremstilling af 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotinsyre eller syreadditionssalte deraf.
BE751898A (nl) Steiger.
DK123293B (da) Analogifremgangsmåde til fremstilling af N-substitueret 1-(2-hydroxy-3-aminopropoxy)-9-fluorenon eller syreadditionssalte heraf.
DK138741B (da) Fremgangsmåde til fremstilling af 1-hydroxyalkyl-1,4-benzodiazepin-2-on-derivater eller syreadditionssalte deraf.
ES196125Y (es) Andamio colgante.
DK122813B (da) Analogifremgangsmåde til fremstilling af benzofuranderivater eller syreadditionssalte deraf.
DK137573C (da) Fremgangsmaade til fremstilling af 7-chlor-1,3-dihydro-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-on
DK123773B (da) Fremgangsmåde til fremstilling af chromogene, heterocykliske phthalider.
DK122075B (da) Fremgangsmåde til fremstilling af chromogene, heterocykliske phthalider.
DK121954B (da) Fremgangsmåde til fremstilling af chromogene, heterocykliske phthalider.